Promoter stake sale puts Gland Pharma in focus

witnessed a block deal involving 75 lakh shares, equivalent to around 4.5% of the company, worth approximately ₹2,121 crore at an average price of about ₹2,828 per share. The transaction comes after reports that promoter Fosun Pharma Industrial was looking to reduce its holding. The stake sale needs to be viewed alongside Gland Pharma’s strong recent operating performance. In Q1 FY27, consolidated revenue increased 20% YoY to ₹1,800 crore, while net profit rose 47% to ₹317 crore. Adjusted EBITDA grew 37% YoY, with the margin at around 28%. The company’s CDMO business contributed nearly half of revenue and grew 20% YoY, while the B2B business grew 19%. Importantly, Gland Pharma recently received a positive regulatory signal after its USFDA inspection of the VSEZ sterile oncology formulations and API facilities concluded with zero Form 483 observations. The company has also announced strategic CDMO partnerships, supporting its longer-term growth prospects. However, the promoter stake reduction could create near-term supply pressure and investor sentiment concerns, particularly after the stock’s strong rally. Fosun Pharma held 51.77% as of June 2026, so investors should track its post-transaction ownership and any further selling restrictions. Overall, strong earnings growth, CDMO expansion and favourable USFDA developments remain positive catalysts. However, promoter selling and potential further stake dilution could weigh on the stock in the near term.